A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Trial Profile

A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use
  • Acronyms PIONEER-HCM
  • Sponsors MyoKardia
  • Most Recent Events

    • 18 Sep 2017 Data presented in a MyoKardia Media Release.
    • 18 Sep 2017 According to a MyoKardia media release, additional positive data from the first patient cohort, supported the addition of a second, low-dose cohort in this trial.
    • 18 Sep 2017 According to a MyoKardia media release, additional data from the first patient cohort of this study were presented at at the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top